Please assess the completion status of the following clinical trial:

Trial Title: Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women \>18 years~* Liver cirrhosis confirmed by fibroscan (\>20 kPa), or by imaging with signs of an irregular liver surface with collaterals, or clinically by cirrhosis stigmata~* Refractory ascites Definition: failure to respond to or intolerance to high dose diuretics (spironolactone up to 400mg/day and furosemide up to 160mg/day) and early ascites recurrence (reappearance of grade 2 or 3 ascites within 4 weeks of initial mobilization or ≥2 paracentesis within last 3 months)~* Urine sodium excretion \<60 mmol/24 hour~* Serum creatinine \<150 µmol/L~* Child-Turcotte-Pugh score of B or C (\<13)~* Bilirubin \<150 µmol/L~* Prothrombin time (PP) 0.20-0.60 (INR 1.3-2.5)~* Systolic blood pressure ≥95 mmHg~* Written informed consent to participate in the clinical trial~Exclusion Criteria:~* Gastrointestinal bleeding within 2 weeks prior to inclusion~* Proteinuria \>500 mg/day~* Hemoglobin \<5.5 mmol/L~* Spontaneous bacterial peritonitis within 2 weeks prior to inclusion~* Loculated ascites~* Hepatic encephalopathy grade 2-4 (West-Haven classification)~* Obstructive uropathy~* Primary kidney disease~* Known diagnosis of congestive heart failure~* Known diagnosis of acute-on-chronic liver failure~* Known diagnosis of systemic inflammatory response syndrome~* Acute infections by known diagnosis and/or antibiotic treatment~* Known HIV infection~* Known allergy to the investigational drug or other natriuretic peptides~* Treatment with dobutamine, levosimendan, milrinone, any phosphodiesterase inhibitor, octreotide, midodrine, vasopressin, dopamine or other vasopressors within 2 weeks prior to inclusion~* Nephrotoxic drugs within 1 month prior to inclusion~* Fertile women not using contraception, either an intrauterine device or hormonal contraception~* Positive pregnancy test in pre-menopausal women or in breast-feeding women~* Participation in an interventional clinical drug trial within 1 month prior to inclusion~* Legal incapacity or limited legal capacity~* Patients who are employees or relatives of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ularitide (Type: EXPERIMENTAL): Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo. Continuous IV infusion for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).